Skyhawk
Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research
Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development
Actionable Insights Powered by AI
Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development